You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

CLINICAL TRIALS PROFILE FOR CLOFIBRATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Clofibrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000482 ↗ Coronary Drug Project Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1965-04-01 To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.
NCT00000483 ↗ Coronary Drug Project Mortality Surveillance Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 1981-06-01 To determine whether there were any long term sequelae of the drugs used in the Coronary Drug Project (estrogens, dextrothyroxine, nicotinic acid, clofibrate).
NCT00238004 ↗ The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status Craigavon Area Hospital Phase 4 2005-11-01 Abnormal blood cholesterol levels increase the risk of developing, or dying from heart disease. It is well recognised that if "harmful" LDL cholesterol is high, and "protective" HDL cholesterol is low, this risk is increased. Drugs called statins are routinely used in patients with heart disease, are well tolerated, and decrease the harmful LDL cholesterol levels. However, statins only increase protective HDL cholesterol to a small extent. Some patients may thus benefit from additional medication to increase protective HDL-cholesterol further. One of the most effective drugs which can do this is nicotinic acid. This drug is well established having been available for over 30 years. Previous use has been limited by facial flushing in a large percentage of patients receiving the drug. However a new formulation called Niaspan is now available which is associated with much less flushing. Although many patients will have transient flushing, it is estimated that only 1 patient out of every 20 receiving the drug will have to discontinue treatment. We therefore propose, in patients with coronary artery disease and low HDL cholesterol despite being on a statin, to study the effect of Niaspan on HDL cholesterol and other lipid parameters, and to assess its tolerability.
NCT00311987 ↗ Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients Terminated Johns Hopkins University Phase 1/Phase 2 2006-04-01 The natural thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are known to have a cholesterol-lowering effect. Their pharmacologic use for this purpose is limited, however, by their actions on other organs, including the heart, bone, and brain, where there can be side effects of excessive thyroid hormone action. 3,5-diiodothyropropionic acid (DITPA) is a thyroid hormone analog with relative selectivity for a form of the thyroid hormone receptor expressed in the liver, where it regulates several aspects of lipid metabolism, including the clearance of low-density lipoprotein (LDL) cholesterol. This study is designed to determine whether DITPA is safe and effective in achieving LDL cholesterol levels that are consistent with the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines in patients who have not achieved those levels on conventional therapy, due to drug-resistant disease, drug intolerance, or both. This is a single-center, randomized, double-blind, placebo-controlled study. Following a 4-week Pre-Randomization Phase with dietary counseling and a 2-week placebo run-in, eligible patients will be randomized (1:1:1) to receive DITPA (90 mg/day, 180 mg/day), or placebo for a total treatment duration of 12 weeks. Sixty (60) patients will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (i.e., 20 patients per treatment group): - DITPA at 90 mg/day (45 mg twice a day [BID] taken orally) - DITPA at 180 mg/day (90 mg BID taken orally) - Placebo (BID taken orally) Those patients randomized to receive DITPA at 90 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for 10 weeks. Those patients randomized to receive DITPA at 180 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for the next 2 weeks, and then 180 mg/day for 8 weeks.
NCT00983788 ↗ Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects Completed Groupe Hospitalier Pitie-Salpetriere Phase 2 2009-10-01 The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies. This study will be an 9-month, randomized, double-blind, placebo-controlled crossover trial. The trial will be conducted in two centers: Institut de Myologie, Pitié-Salpêtrière Hospital in France, and Rigshospitalet, University of Copenhagen, in Denmark. The main criteria for assessing the potential effect of this drug will be the fat oxidation rate studied during a moderate workload on cycle ergometer, after infusion of stable isotopes (palmitate and glucose tracers).
NCT00983788 ↗ Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects Completed Rigshospitalet, Denmark Phase 2 2009-10-01 The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies. This study will be an 9-month, randomized, double-blind, placebo-controlled crossover trial. The trial will be conducted in two centers: Institut de Myologie, Pitié-Salpêtrière Hospital in France, and Rigshospitalet, University of Copenhagen, in Denmark. The main criteria for assessing the potential effect of this drug will be the fat oxidation rate studied during a moderate workload on cycle ergometer, after infusion of stable isotopes (palmitate and glucose tracers).
NCT01876810 ↗ Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction Completed Centre for Addiction and Mental Health Phase 2 2014-02-01 The purpose of this study is to investigate the effect of gemfibrozil on nicotine reinforcement and cue-elicited craving. Other objectives of this study include screening for the ability of gemfibrozil to aid smoking abstinence during a brief quit attempt and examining the validity of using laboratory measures of tobacco dependence to predict smoking abstinence. It is hypothesized that gemfibrozil will result in diminished nicotine reinforcement, an attenuated response to smoking cues, and an increase in smoking abstinence compared with placebo. It is also hypothesized that the laboratory measures will prove valid in predicting abstinence.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clofibrate

Condition Name

Condition Name for Clofibrate
Intervention Trials
Myocardial Infarction 2
Cardiovascular Diseases 2
Myocardial Ischemia 2
Coronary Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Clofibrate
Intervention Trials
Coronary Artery Disease 3
Myocardial Ischemia 3
Heart Diseases 2
Coronary Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Clofibrate

Trials by Country

Trials by Country for Clofibrate
Location Trials
United States 1
Brazil 1
United Kingdom 1
Canada 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Clofibrate
Location Trials
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Clofibrate

Clinical Trial Phase

Clinical Trial Phase for Clofibrate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Clofibrate
Clinical Trial Phase Trials
Completed 5
Unknown status 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Clofibrate

Sponsor Name

Sponsor Name for Clofibrate
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 2
Fundação de Amparo à Pesquisa do Estado de São Paulo 1
Federal University of São Paulo 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Clofibrate
Sponsor Trials
Other 8
NIH 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clofibrate: Clinical Trials, Market Analysis, and Projections

Introduction to Clofibrate

Clofibrate is a fibrate drug used to manage high cholesterol and triglyceride levels in the blood. It belongs to a class of medications known as fibrates, which are preferred by doctors for their efficacy in improving lipid profiles.

Clinical Trials and Efficacy

Historical Trials

Clofibrate has been studied in various clinical trials over the years. One notable study compared the hypolipidemic effects of halofenate, clofibrate, and placebo in 29 patients with type IV hyperlipoproteinemia. This trial highlighted the ability of clofibrate to reduce lipid levels, although it also noted other laboratory and clinical effects that needed careful monitoring[4].

Current Context

While clofibrate is not as prominently featured in recent clinical trials as other fibrates like fenofibrate, its historical data continues to inform the broader understanding of fibrate efficacy. Recent trials have focused more on newer fibrates, but the foundational work done with clofibrate remains relevant.

Market Analysis

Global Fibrate Drugs Market

The global fibrate drugs market, which includes clofibrate, is anticipated to grow significantly over the coming years. Here are some key points:

  • Market Size: The fibrate drugs market was valued at USD 3.18 billion in 2023 and is expected to grow to USD 5.04 billion by 2032, exhibiting a CAGR of 5.3% during the forecast period[2][3].
  • Segmentation: The market is segmented by drug type, with clofibrate being one of the key segments along with fenofibrates, fenofibric acids, and gemfibrozil. Fenofibrates are currently the dominant segment due to their high efficacy and increasing patient base[2][3].

Regional Market Share

  • North America: This region holds the largest market share due to the high incidence of coronary heart disease and elevated serum cholesterol levels. The detection of CHD and the need for lipid-lowering therapies drive the market in this region[2][3].
  • Asia Pacific: This region is expected to expand at the highest CAGR during the forecast period, driven by a large population with sedentary lifestyles, smoking and drinking habits, and increasing prevalence of diabetes and coronary artery disease[2].

Market Projections

Growth Drivers

  • Increasing Triglyceride Levels: Rising levels of triglycerides among a large group of patients are a primary driver for market growth. High risks of heart attack and stroke associated with elevated triglycerides and low cholesterol levels further drive the demand for fibrate drugs[2][3].
  • Lifestyle Factors: A large population pool using alcohol excessively and leading sedentary lifestyles increases the risk of dyslipidemia, contributing to market growth[2].
  • Research and Development: Ongoing research and development activities for managing high triglyceride levels will continue to support the growth of the fibrate drugs market[2].

Competitive Insights

  • Branded vs Generic: The branded segment currently dominates the market due to patents owned by key players. However, the entry of generic drug manufacturers is expected to increase competition in the coming years[2].
  • Key Players: Companies like Viatris Inc., Aurobindo Pharma, Lupin Pharmaceuticals, Inc., and AbbVie Inc. are major players in the fibrate drugs market[2].

Product Form and Distribution

Product Forms

  • Tablets and Capsules: Fibrate drugs, including clofibrate, are available in tablet and capsule forms. The tablets segment is expected to witness significant growth due to the ability to accommodate higher doses and longer shelf life[2].

Distribution Channels

  • Hospital & Retail Pharmacies: These channels accounted for the largest market share in 2023, driven by the high incidence of heart diseases and the growing number of patients requiring lipid-lowering therapies[2].

Key Takeaways

  • Market Growth: The global fibrate drugs market, including clofibrate, is projected to grow at a CAGR of 5.3% from 2023 to 2032.
  • Dominant Segment: Fenofibrates currently dominate the market, but clofibrate remains a significant part of the fibrate drugs segment.
  • Regional Focus: North America holds the largest market share, while the Asia Pacific region is expected to grow at the highest CAGR.
  • Growth Drivers: Increasing triglyceride levels, lifestyle factors, and ongoing research and development activities drive market growth.

FAQs

What is the current market size of the global fibrate drugs market?

The global fibrate drugs market was valued at USD 3.18 billion in 2023[2].

What is the projected growth rate of the fibrate drugs market?

The market is expected to grow at a CAGR of 5.3% from 2023 to 2032[2].

Which segment dominates the fibrate drugs market?

The fenofibrate segment currently dominates the market due to its high efficacy and increasing patient base[2][3].

What are the primary drivers of the fibrate drugs market growth?

The primary drivers include increasing triglyceride levels, high risks of heart attack and stroke, lifestyle factors, and ongoing research and development activities[2].

Which region is expected to grow at the highest CAGR?

The Asia Pacific region is expected to expand at the highest CAGR during the forecast period[2].

What are the common forms of fibrate drugs?

Fibrate drugs, including clofibrate, are available in tablet and capsule forms, with the tablets segment expected to witness significant growth[2].

Sources

  1. NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib - NewAmsterdam Pharma.
  2. Fibrate Drugs Market Size, Demand, Trends, Report, 2024-2032 - Polaris Market Research.
  3. Global Fibrate Drugs Market: Global Industry Analysis and Forecast (2023 - 2029) - Maximize Market Research.
  4. One-year trials with halofenate, clofibrate, and placebo - PubMed.
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.